142 related articles for article (PubMed ID: 25432369)
1. [Clinical study on chemotherapy of lobaplatin combined with docetaxel in patients with relapsed ovarian cancer].
Li X; Li Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Nov; 39(11):1131-6. PubMed ID: 25432369
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.
Sorbe B; Graflund M; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
Int J Gynecol Cancer; 2012 Jan; 22(1):47-53. PubMed ID: 22193643
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation.
Sorbe B; Graflund M; Nygren L; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
Int J Oncol; 2012 Mar; 40(3):773-81. PubMed ID: 22159569
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.
Wenham RM; Lapolla J; Lin HY; Apte SM; Lancaster JM; Judson PL; Gonzalez-Bosquet J; Herschberger A; Havrilesky LJ; Secord AA
Gynecol Oncol; 2013 Jul; 130(1):19-24. PubMed ID: 23623830
[TBL] [Abstract][Full Text] [Related]
6. Pilot study of docetaxel combined with lobaplatin or gemcitabine for recurrent and metastatic breast cancer.
Li F; Wang B; He M; Chang J; Li J; Shan L; Wang H; Hong W; Luo D; Song Y; Liu L; Li H; Ran L; Chen T
Medicine (Baltimore); 2019 Dec; 98(52):e18513. PubMed ID: 31876741
[TBL] [Abstract][Full Text] [Related]
7. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
Sun X; Lou LG; Sui DH; Wu XH
Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
[TBL] [Abstract][Full Text] [Related]
8. Single-arm, multi-centre phase II study of lobaplatin combined with docetaxel for recurrent and metastatic nasopharyngeal carcinoma patients.
Long GX; Lin JW; Liu DB; Zhou XY; Yuan XL; Hu GY; Mei Q; Hu GQ
Oral Oncol; 2014 Aug; 50(8):717-20. PubMed ID: 24844985
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer.
Anwer K; Kelly FJ; Chu C; Fewell JG; Lewis D; Alvarez RD
Gynecol Oncol; 2013 Oct; 131(1):169-73. PubMed ID: 23863356
[TBL] [Abstract][Full Text] [Related]
10. Lobaplatin combined with docetaxel neoadjuvant chemotherapy followed by concurrent lobaplatin with intensity-modulated radiotherapy increases the survival of patients with high-risk lymph node positive nasopharyngeal carcinoma.
Zhang S; Lin S; Hu L
J BUON; 2016; 21(1):161-7. PubMed ID: 27061544
[TBL] [Abstract][Full Text] [Related]
11. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
[TBL] [Abstract][Full Text] [Related]
13. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.
Gietema JA; Veldhuis GJ; Guchelaar HJ; Willemse PH; Uges DR; Cats A; Boonstra H; van der Graaf WT; Sleijfer DT; de Vries EG
Br J Cancer; 1995 Jun; 71(6):1302-7. PubMed ID: 7779728
[TBL] [Abstract][Full Text] [Related]
14. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
[TBL] [Abstract][Full Text] [Related]
15. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
16. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
Armstrong DK; White AJ; Weil SC; Phillips M; Coleman RL
Gynecol Oncol; 2013 Jun; 129(3):452-8. PubMed ID: 23474348
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center.
Zhang G; Li XP; Liu BJ; Wang JL; Wang SJ; Cui H; Wei LH
Chin Med J (Engl); 2013 Dec; 126(23):4477-82. PubMed ID: 24286410
[TBL] [Abstract][Full Text] [Related]
18. Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG).
Koinis F; Polyzos A; Christopoulou A; Zafeiriou Z; Emmanouilidis C; Papadimitraki E; Kalykaki A; Kalbakis K; Samonis G; Georgoulias V
Cancer Chemother Pharmacol; 2014 Apr; 73(4):819-25. PubMed ID: 24531559
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial.
Ke LR; Xia WX; Qiu WZ; Huang XJ; Yang J; Yu YH; Liang H; Liu GY; Ye YF; Xiang YQ; Guo X; Lv X
BMC Cancer; 2017 Feb; 17(1):134. PubMed ID: 28202000
[TBL] [Abstract][Full Text] [Related]
20. ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
Lee M; Kim SW; Nam EJ; Cho H; Kim JH; Kim YT; Kim S
Yonsei Med J; 2014 Nov; 55(6):1664-71. PubMed ID: 25323906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
